Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial-Reference-Cited by-同舟云学术

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

Published:2011-04 Issue:9773 Volume:377 Page:1256-1263
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Griffiths Paul D,Stanton Anna,McCarrell Erin,Smith Colette,Osman Mohamed,Harber Mark,Davenport Andrew,Jones Gareth,Wheeler David C,O'Beirne James,Thorburn Douglas,Patch David,Atkinson Claire E,Pichon Sylvie,Sweny Paul,Lanzman Marisa,Woodford Elizabeth,Rothwell Emily,Old Natasha,Kinyanjui Ruth,Haque Tanzina,Atabani Sowsan,Luck Suzanne,Prideaux Steven,Milne Richard SB,Emery Vincent C,Burroughs Andrew K

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Vaccines for the 21st Century (2001);Stratton,2001

2. Progress toward an elusive goal: current status of cytomegalovirus vaccines;Schleiss;Expert Rev Vaccines,2005

3. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee;Arvin;Clin Infect Dis,2004

4. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus;Grundy;Lancet,1988

5. Cytomegalovirus reinfections in healthy seroimmune women;Ross;J Infect Dis,2010

Cited by 356 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update;Transplantation Reviews;2024-12

3. Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation;Proceedings of the National Academy of Sciences;2024-09-04

4. Designing multi-epitope vaccine against human cytomegalovirus integrating pan-genome and reverse vaccinology pipelines;Biologicals;2024-08

5. Evaluating longitudinal cytomegalovirus-specific humoral immune responses and association with DNAemia risk in seropositive lung transplant recipients;JHLT Open;2024-08